• The ways of using L-arginine in obstetrics and gynecology to treat diseases, which have an endothelium disfunction in their basis

The ways of using L-arginine in obstetrics and gynecology to treat diseases, which have an endothelium disfunction in their basis

HEALTH OF WOMAN. 2017.2(118):50–54; doi 10.15574/HW.2017.118.50

Gopchuk E.
Shupyk National Medical Academy of Postgraduate Education, Kiev

The objective: to investigate the clinical efficacy of the drug Tivomax (arginine hydrochloride 42 mg/ml) at a dose of 100 ml intravenously 1 time a day course 10 days for medical correction of placental dysfunction.

Patients and methods. Under our supervision there were 30 pregnant women at term 32-34 weeks with circulatory disorders in the system mother-placenta-fetus. To assess the functional state of the fetoplacental complex used sonometric methods, Doppler Velocimetry of blood flow in the placental system and the definition of biophysical profile of the fetus.

Results. The study of peculiarities of haemodynamics in the mother-placenta-fetus was discovered isolated changes in blood flow of uterine arteries in 14 (46.7%) women, accompanied by: a decrease in the diastolic component in the end-diastolic velocity krovotoka – 42.3±2.14 cm/s, increased resistance index – 0.65±0.08 and systolo-diastolic ratio was 2.47±0.32. Violation of placental blood flow was observed in 11 (36.7%) patients. All the patients for the correction of violations was given the drug Tivomax.

Conclusion. Tivomax as a donor L-arginine has pronounced effect on the vascular tone as the uterine arteries, and arteries of the umbilical cord, contributing to the normalization of hemodynamics in the mother-placenta-fetus.

Key words: Tivomax, L-arginine, endothelium. Obstetrics and gynecology, placental deficiency, preeclampsia

REFERENCES

1. Bloschinskaya IA. 2003. Funktsionalnoe sostoyanie sosudistogo endoteliya i narusheniya mikrotsirkulyatsii pri beremennosti, oslozhnennoy gestozom i vliyanie na nih normobaricheskoy gipoksiterapii. Avtoref. diss. kand. med. nauk. Tomsk:36.

2. Gorpinchenko II, Miroshnikov YaO. 2009. Erektilnaya disfunktsiya. Meditsina svItu:85.

3. Lechenie erektilnoy disfunktsii. Pod redaktsiey prof. II Gorpinchenko. K, Izd. dom «Professional». 2008:191.

4. Bikmetova ES, Trishkin AG, Artyimuk NV. 2012. Zaderzhka rosta ploda. Chastota, faktoryi riska. Mat i ditya v Kuzbasse 1:27–31.

5. Slyusar TI, Pilipenko ON, Dzhelomanova OA, Levchenko II. 2015. Izmenenie pokazateley fetoplatsentarnogo kompleksa u patsientok s zaderzhkoy vnutriutrobnogo razvitiya ploda i antenatalnyimi poteryami v anamneze. Zdorove zhenschinyi 3:156–158.

6. Fedorova MV. 1997. Platsentarnaya nedostatochnost. Akusherstvo i ginekologiya 6:40–43.

7. Kovalev EV, Lazuko SS, Zanko YuV. 2015. Diagnosticheskaya znachimost opredeleniya indutsibelnoy no-sintazyi v diagnostike zaderzhki rosta ploda v tretem trimestre beremennosti. Ohrana materinstva i detstva 1:36–40.

8. Linde VA, Pogorelova TN, Drukker NA i dr. 2011. Rol argininovogo disbalansa v razvitii platsentarnoy nedostatochnosti. Akusherstvo i ginekologiya 4:26–30.

9. Golovchenko YuI, Treschinskaya MA. 2008. Obzor sovremennyih predstavleniy ob endotelialnoy disfunktsii. Consilium medicum Ukraina. 11:38-40.

10. Gurevich MA, Sturov NV. 2006. Defitsit oksida azota i podderzhanie sosudistogo gomeostaza: rol mononitratov i problemyi tsitoprotektsii. Trudnyiy patsient 3:23–29.

11. Lutsenko NS, Geraskina LR, Evtereva IA i soavt. 2009. Nekotoryie mehanizmyi aktivatsii proliferativnyih protsessov v organah reproduktivnoy sistemyi. Mediko-sotsIalnI problemi sIm’Yi 14;4:134–139.

12. Serov VN, Prilepskaya VN, Ovsyannikova TV. 2004. Ginekologicheskaya endokrinologiya. M, MEDpress-inform:520.

13. Gorpinchenko II. 2012. Muzhchina v XXI veke. Seksologicheskie i andrologicheskie aspektyi. Zdorove muzhchinyi 4:15–18.

14. Babushkina AV. 2009. L-arginin s tochki zreniya dokazatelnoy meditsinyi. Ukr. Med. Chasopis 6(74):1–6.

15. Guimarges MF, Brandgo AH, Rezende CA. 2014. Assessment of endothelial function in pregnant women. Arch Gynecol Obstet. 290:441–447.

16. Bird IM, Boeldt DS, Krupp J. 2013. Pregnancy, programming and preeclampsia: gap junctions at the nexus of pregnancy-induced adaptation of endothelial function and endothelial adaptive failure in PE. Current Vascular Pharmacology. 11:712–729. https://doi.org/10.2174/1570161111311050009; PMid:24063383

17. Schroeder BM. 2012. ACOG practice bulletin on diagnosing and managing preeclampsia and eclampsia. American College of Obstetricians and Gynecologists. Am Fam Physician. 66:330–331.

18. Roberts JM, Lain KY. 2012. Recent Insights into the pathogenesis of pre-eclampsia. Placenta. 23:359–372. https://doi.org/10.1053/plac.2002.0819; PMid:12061851

19. Baschat AA. 2010. Fetal growth restriction – from observation to intervention. J. Perinat. Med. 38;3:239–246. https://doi.org/10.1515/jpm.2010.041

20. Gornik HL, Creager MA. 2004. Arginine and endothelial and vascular health. J.Nutr. 134:2880S–2887S. PMid:15465805

21. Neri I, Jasonni VM, Gori GF. 2006. Effect of L-arginine on blood pressure in pregnancy induced hypertension: a randomized placebo-controlled trial. J. Matern. Fetal Neonatal. Med. 19(5):277–281. https://doi.org/10.1080/14767050600587983; PMid:16753767

22. Savvidou MD, Hingorani AD, Tsikas D. 2003. Endothelial dysfunction and raised plasma concentrations of asymmetric dimetylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 361:1511–1517. https://doi.org/10.1016/S0140-6736(03)13177-7

23. Boger RH, Bode-Boger SM. 2001. The clinical pharmacology of l-arginine. Annu Rev Pharmacol Toxicol. 41:79–99. https://doi.org/10.1146/annurev.pharmtox.41.1.79; PMid:11264451

24. Sieroszewski P, Suzin J, Karowicz-Bilinska A. 2004. Ultarsound evaluation of intrauterine growth restriction therapy by a nitric oxide donor (l-arginine). J Matern Fetal Neonatal Med. 15:363–366. https://doi.org/10.1080/14767050410001725280; PMid:15280105

25. Pace VD, Chiossi G, Facchinetti F. 2007. Clinical use of nitric oxide donors and l-arginine in obstetrics. J Matern Fetal Neonatal Med. 20(8):569–579. https://doi.org/10.1080/14767050701419458; PMid:17674274

26. Rytlewski K, Olszanecki R, Korbut R. 2005. Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide. Eur J Clin Invest. 35:32–37. https://doi.org/10.1111/j.1365-2362.2005.01445.x; PMid:15638817

27. Young BC, Levine RJ, Karumanchi SA. 2010. Pathogenesis of preeclampsia. Annu Rev Pathol. 5:173–192. https://doi.org/10.1146/annurev-pathol-121808-102149; PMid:20078220

28. Catov JM, Nohr EA, Bodnar LM. 2009. Association of periconceptional multivitamin use with reduced risk of preeclampsia among normal-weight women in the Danish National Birth Cohort. Am J Epidemiol. 169:1304-1311. https://doi.org/10.1093/aje/kwp052; PMid:19372217 PMCid:PMC2727249

29. Venkatesha S, Toporsian M, Lam C. 2006. Soluble endoglin contributes to the pathogenesis of pre-eclampsia. Nat Med. 12:642–649. https://doi.org/10.1038/nm0706-862c; https://doi.org/10.1038/nm1429; PMid:16751767

30. Böger RH. 2007. The pharmacodynamics of L-arginine. J.Nutr. 137:1650S–1655S. PMid:17513442

31. Yi J, Horky LL, Friedlich AL. 2009. L-arginine and Alzheimer’s disease. Int J Clin Exp Pathol. 2(3):211–238. PMid:19079617

32. Meher S, Duley L. 2007. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2:48–51. https://doi.org/10.1002/14651858.cd006490

33. Mangoni AA, Ouldred E, Swif CG. 2011. Vascular and blood pressure effects of L-arginine. J Matern Fetal Neonatal Med. 49:1003–1004.

Содержание журнала Full text of article